Published on 16 Mar 2024 on Simply Wall St. via Yahoo Finance
Spruce Biosciences, Inc. (NASDAQ:SPRB) investors will be delighted, with the company turning in some strong numbers with its latest results. The results overall were credible, with revenues of US$10m beating expectations by 18%. Statutory losses were US$1.24 per share, 11% below what the analysts had forecast. Earnings are an important time for investors, as they can track a company's performance, look at what the analysts are forecasting for next year, and see if there's been a change in sentiment towards the company. We thought readers would find it interesting to see the analysts latest (statutory) post-earnings forecasts for next year.
See our latest analysis for Spruce Biosciences
earnings-and-revenue-growth